Pendal Group Ltd Has $1.06 Million Stock Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Pendal Group Ltd lifted its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 5.3% during the second quarter, HoldingsChannel reports. The fund owned 12,350 shares of the biotechnology company’s stock after purchasing an additional 622 shares during the quarter. Pendal Group Ltd’s holdings in BioMarin Pharmaceutical were worth $1,058,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Rational Advisors LLC increased its position in BioMarin Pharmaceutical by 3,211.1% during the first quarter. Rational Advisors LLC now owns 298 shares of the biotechnology company’s stock worth $26,000 after buying an additional 289 shares during the last quarter. Berman Capital Advisors LLC increased its position in BioMarin Pharmaceutical by 56.8% during the first quarter. Berman Capital Advisors LLC now owns 417 shares of the biotechnology company’s stock worth $36,000 after buying an additional 151 shares during the last quarter. Twin Tree Management LP acquired a new position in BioMarin Pharmaceutical during the first quarter worth $36,000. Trust Co. of Vermont acquired a new position in BioMarin Pharmaceutical during the first quarter worth $44,000. Finally, Patriot Financial Group Insurance Agency LLC increased its position in BioMarin Pharmaceutical by 34.8% during the first quarter. Patriot Financial Group Insurance Agency LLC now owns 809 shares of the biotechnology company’s stock worth $72,000 after buying an additional 209 shares during the last quarter. 96.86% of the stock is currently owned by institutional investors and hedge funds.

BioMarin Pharmaceutical stock traded up $3.13 during mid-day trading on Friday, hitting $74.86. 33,311 shares of the company’s stock were exchanged, compared to its average volume of 1,105,077. The company has a current ratio of 4.11, a quick ratio of 2.79 and a debt-to-equity ratio of 0.28. BioMarin Pharmaceutical Inc. has a 1-year low of $71.53 and a 1-year high of $106.74. The stock has a 50 day moving average of $80.60 and a two-hundred day moving average of $86.46. The stock has a market cap of $12.87 billion, a P/E ratio of -225.70 and a beta of 1.35.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its quarterly earnings results on Thursday, August 1st. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.05) by ($0.16). BioMarin Pharmaceutical had a negative net margin of 7.19% and a negative return on equity of 3.12%. The firm had revenue of $388.00 million for the quarter, compared to the consensus estimate of $415.03 million. During the same quarter last year, the company earned ($0.09) earnings per share. The firm’s revenue was up 4.0% on a year-over-year basis. As a group, research analysts predict that BioMarin Pharmaceutical Inc. will post -0.03 EPS for the current fiscal year.

In other BioMarin Pharmaceutical news, Director V Bryan Lawlis sold 3,750 shares of the company’s stock in a transaction dated Monday, June 17th. The shares were sold at an average price of $81.08, for a total transaction of $304,050.00. Following the completion of the sale, the director now directly owns 27,340 shares in the company, valued at $2,216,727.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.90% of the stock is owned by corporate insiders.

BMRN has been the topic of several analyst reports. TheStreet downgraded shares of BioMarin Pharmaceutical from a “c-” rating to a “d+” rating in a research report on Tuesday, May 7th. Cantor Fitzgerald reissued a “buy” rating and set a $131.00 target price on shares of BioMarin Pharmaceutical in a research report on Friday, April 26th. BidaskClub downgraded shares of BioMarin Pharmaceutical from a “sell” rating to a “strong sell” rating in a research report on Friday, July 26th. JPMorgan Chase & Co. reissued a “buy” rating and set a $133.00 target price on shares of BioMarin Pharmaceutical in a research report on Monday, August 5th. Finally, Robert W. Baird set a $120.00 target price on shares of BioMarin Pharmaceutical and gave the stock a “buy” rating in a research report on Friday, April 26th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and eleven have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $115.60.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc, a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

Read More: What is a price target?

Want to see what other hedge funds are holding BMRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN).

Institutional Ownership by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.